New Zealand approved the use of MDMA in controlled clinical settings, allowing two psychiatrists to prescribe the substance for the treatment of post-traumatic stress. This decision represents a significant change in the country's therapeutic approach.
The psychiatrists can now use MDMA as part of controlled clinical treatments, following specific protocols to ensure patient safety. The treatment is specifically intended for people suffering from post-traumatic stress.
The decision is based on clinical trials whose results were contested in the United States, creating a debate about the efficacy and safety of this alternative treatment.
